125 related articles for article (PubMed ID: 32882336)
1. Local intracerebral inhibition of IRE1 by MKC8866 sensitizes glioblastoma to irradiation/chemotherapy in vivo.
Le Reste PJ; Pineau R; Voutetakis K; Samal J; Jégou G; Lhomond S; Gorman AM; Samali A; Patterson JB; Zeng Q; Pandit A; Aubry M; Soriano N; Etcheverry A; Chatziioannou A; Mosser J; Avril T; Chevet E
Cancer Lett; 2020 Dec; 494():73-83. PubMed ID: 32882336
[TBL] [Abstract][Full Text] [Related]
2. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
[TBL] [Abstract][Full Text] [Related]
3. A Survival Analysis with Identification of Prognostic Factors in a Series of 110 Patients with Newly Diagnosed Glioblastoma Before and After Introduction of the Stupp Regimen: A Single-Center Observational Study.
Illic R; Somma T; Savic D; Frio F; Milicevic M; Solari D; Nikitovic M; Lavrnic S; Raicevic S; Milosevic S; Cavallo LM; Cappabianca P; Grujicic D
World Neurosurg; 2017 Aug; 104():581-588. PubMed ID: 28522381
[TBL] [Abstract][Full Text] [Related]
4. Cure following gene therapy for recurrent glioblastoma multiforme?
Karabatsou K; Bernstein M
Acta Neurochir (Wien); 2008 Jun; 150(6):611-2. PubMed ID: 18511998
[TBL] [Abstract][Full Text] [Related]
5. Mangiferin induces radiosensitization in glioblastoma cells by inhibiting nonhomologous end joining.
Mu F; Liu T; Zheng H; Xie X; Lei T; He X; Du S; Tong R; Wang Y
Oncol Rep; 2018 Dec; 40(6):3663-3673. PubMed ID: 30272350
[TBL] [Abstract][Full Text] [Related]
6. Enhanced immunosuppression by therapy-exposed glioblastoma multiforme tumor cells.
Authier A; Farrand KJ; Broadley KW; Ancelet LR; Hunn MK; Stone S; McConnell MJ; Hermans IF
Int J Cancer; 2015 Jun; 136(11):2566-78. PubMed ID: 25363661
[TBL] [Abstract][Full Text] [Related]
7. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme.
Rainov NG; Kramm CM; Banning U; Riemann D; Holzhausen HJ; Heidecke V; Burger KJ; Burkert W; Körholz D
Gene Ther; 2000 Nov; 7(21):1853-8. PubMed ID: 11110418
[TBL] [Abstract][Full Text] [Related]
8. ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.
Zhang C; Burger MC; Jennewein L; Genßler S; Schönfeld K; Zeiner P; Hattingen E; Harter PN; Mittelbronn M; Tonn T; Steinbach JP; Wels WS
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26640245
[TBL] [Abstract][Full Text] [Related]
9. Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma.
DeCordova S; Shastri A; Tsolaki AG; Yasmin H; Klein L; Singh SK; Kishore U
Front Immunol; 2020; 11():1402. PubMed ID: 32765498
[TBL] [Abstract][Full Text] [Related]
10. Combination therapy in a xenograft model of glioblastoma: enhancement of the antitumor activity of temozolomide by an MDM2 antagonist.
Wang H; Cai S; Bailey BJ; Reza Saadatzadeh M; Ding J; Tonsing-Carter E; Georgiadis TM; Zachary Gunter T; Long EC; Minto RE; Gordon KR; Sen SE; Cai W; Eitel JA; Waning DL; Bringman LR; Wells CD; Murray ME; Sarkaria JN; Gelbert LM; Jones DR; Cohen-Gadol AA; Mayo LD; Shannon HE; Pollok KE
J Neurosurg; 2017 Feb; 126(2):446-459. PubMed ID: 27177180
[TBL] [Abstract][Full Text] [Related]
11. Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma.
Wirsching HG; Zhang H; Szulzewsky F; Arora S; Grandi P; Cimino PJ; Amankulor N; Campbell JS; McFerrin L; Pattwell SS; Ene C; Hicks A; Ball M; Yan J; Zhang J; Kumasaka D; Pierce RH; Weller M; Finer M; Quéva C; Glorioso JC; Houghton AM; Holland EC
JCI Insight; 2019 Jul; 4(13):. PubMed ID: 31292299
[TBL] [Abstract][Full Text] [Related]
12. BIRC3 is a novel driver of therapeutic resistance in Glioblastoma.
Wang D; Berglund A; Kenchappa RS; Forsyth PA; Mulé JJ; Etame AB
Sci Rep; 2016 Feb; 6():21710. PubMed ID: 26888114
[TBL] [Abstract][Full Text] [Related]
13. Success and Failures of Combined Modalities in Glioblastoma Multiforme: Old Problems and New Directions.
Corso CD; Bindra RS
Semin Radiat Oncol; 2016 Oct; 26(4):281-98. PubMed ID: 27619250
[TBL] [Abstract][Full Text] [Related]
14. Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome.
Cesarini V; Martini M; Vitiani LR; Gravina GL; Di Agostino S; Graziani G; D'Alessandris QG; Pallini R; Larocca LM; Rossi P; Jannini EA; Dolci S
Oncotarget; 2017 Feb; 8(8):13223-13239. PubMed ID: 28099939
[TBL] [Abstract][Full Text] [Related]
15. Activation of the Unfolded Protein Response via Inhibition of Protein Disulfide Isomerase Decreases the Capacity for DNA Repair to Sensitize Glioblastoma to Radiotherapy.
Liu Y; Ji W; Shergalis A; Xu J; Delaney AM; Calcaterra A; Pal A; Ljungman M; Neamati N; Rehemtulla A
Cancer Res; 2019 Jun; 79(11):2923-2932. PubMed ID: 30996048
[TBL] [Abstract][Full Text] [Related]
16. Glioblastoma multiforme: a review of therapeutic targets.
Kanu OO; Mehta A; Di C; Lin N; Bortoff K; Bigner DD; Yan H; Adamson DC
Expert Opin Ther Targets; 2009 Jun; 13(6):701-18. PubMed ID: 19409033
[TBL] [Abstract][Full Text] [Related]
17. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
[TBL] [Abstract][Full Text] [Related]
18. NKG2D-Dependent Antitumor Effects of Chemotherapy and Radiotherapy against Glioblastoma.
Weiss T; Schneider H; Silginer M; Steinle A; Pruschy M; Polić B; Weller M; Roth P
Clin Cancer Res; 2018 Feb; 24(4):882-895. PubMed ID: 29162646
[No Abstract] [Full Text] [Related]
19. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme.
Phuong LK; Allen C; Peng KW; Giannini C; Greiner S; TenEyck CJ; Mishra PK; Macura SI; Russell SJ; Galanis EC
Cancer Res; 2003 May; 63(10):2462-9. PubMed ID: 12750267
[TBL] [Abstract][Full Text] [Related]
20. A tumor-targeting nanomedicine carrying the p53 gene crosses the blood-brain barrier and enhances anti-PD-1 immunotherapy in mouse models of glioblastoma.
Kim SS; Harford JB; Moghe M; Slaughter T; Doherty C; Chang EH
Int J Cancer; 2019 Nov; 145(9):2535-2546. PubMed ID: 31241175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]